Angelo F. Scinto
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.
Journal: NPJ breast cancer
Published: November 11, 2019
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence.
Journal: Journal of cellular physiology
Published: November 08, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Journal: International journal of cancer
Published: April 15, 2019
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Journal: Cancer biology & therapy
Published: November 08, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.
Journal: Journal of cellular physiology
Published: October 10, 2018
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.
Journal: Oncotarget
Published: March 07, 2017
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.
Journal: Scientific reports
Published: March 03, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026